Targeting the resistance of glioblastoma stem cells to improve treatment outcomes
Targeting Malignant Reprogramming of Glioblastoma Stem Cells Through Dual Inhibition of S6K1 and BIRC3
This study is looking at new ways to treat glioblastoma, a tough brain cancer, by focusing on the stem cells that help it grow and resist treatment, with the hope of finding better therapies that could help patients live longer and feel better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project ID | NIH-11002301 on NIH RePORTER |
What this research studies
This research focuses on glioblastoma, a highly aggressive brain cancer that is often resistant to current treatments. The team aims to develop new therapies that specifically target the malignant reprogramming of glioblastoma stem cells, which contribute to the cancer's lethality. By investigating the interactions between specific proteins involved in cancer cell survival and resistance, the researchers hope to identify effective strategies to prevent the evolution of these cells into more aggressive forms. Patients may benefit from innovative treatments that could enhance survival rates and improve quality of life.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma who are seeking new treatment options.
Not a fit: Patients with other types of brain tumors or those who are not diagnosed with glioblastoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly improve survival rates for patients with glioblastoma.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways in glioblastoma, indicating potential for success in this approach.
Where this research is happening
Tampa, United States
- H. Lee Moffitt Cancer Ctr & Res Inst — Tampa, United States (Active)
Researchers
- Principal investigator: Etame, Arnold — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Etame, Arnold
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.